NetJets Empowers Pilots With Cutting-Edge Safety Analytics From FlightPulse ®
FlightPulse ® will equip NetJets' more than 4,400 pilots globally with secure, consolidated flight data to drive informed decisions on risk management, aircraft functionality and fuel, and their own performance, fostering continuous self-improvement. NetJets is the first private jet operator of its kind to embrace the technology, which it plans to begin deploying by the end of the year.
'In the world of aviation, safety is paramount and will always be NetJets' first and highest priority, integral to every decision we make,' said Adam Johnson, NetJets Chairman and CEO. 'As the industry leader, it is our responsibility to elevate our safety programs by utilizing cutting-edge tools like FlightPulse ® to continue to bring best-in-class service to our customers worldwide.'
Designed by pilots, for pilots, FlightPulse ® is a fully configurable, modular Electronic Flight Bag (EFB) application. By putting important operational data directly in the hands of pilots, FlightPulse ® empowers aviators to make more informed decisions, self-critique recent flight profiles, and compare themselves to their peers. FlightPulse ® offers integrated pre- and postflight modules that deliver essential safety and sustainability insights about flight paths that help pilots bolster their flying performance.
As an extension of GE Aerospace's Flight Operations Quality Assurance (FOQA) program, FlightPulse ® enables operators to provide crewmembers with rapid feedback on flight performance and insights to enhance safety and aid decision-making. On any given day, FlightPulse ® processes data from an average of 2.5 million flights, providing pilots with comprehensive, data-driven insights to support safer and more efficient operations.
"We are proud to collaborate with NetJets as they adopt GE Aerospace's FlightPulse ® software to enhance pilot decision-making and operational performance,' said Andrew Coleman, President and General Manager, GE Aerospace's Software as a Service. 'This collaboration marks a significant milestone, expanding the global reach of business jet pilots using our software. Together, we are helping to drive innovation and safety in aviation by providing pilots with actionable, data-driven insights to optimize every flight."
Similar to its implementation of FlightPulse ®, NetJets was the first shared ownership provider to establish a FOQA program, which has successfully produced actionable discoveries and strengthened safety margins. FlightPulse ® is one of NetJets' newest tools to support its enduring efforts to elevate safety for pilots and passengers.
About NetJets
Originally incorporated in 1964 as Executive Jet Airways, NetJets has been setting—and exceeding—industry standards for more than 60 years. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety and service. The NetJets portfolio of distinctive companies, encompassing NetJets, Executive Jet Management, QS Partners, and QS Security, offers a variety of customizable travel solutions, including shared ownership, lease and jet card options, aircraft management, private jet chartering, brokerage and acquisition services, and specialized security services. This comprehensive suite of solutions is why so many of the world's most discerning travelers choose NetJets generation after generation. It is also because NetJets has the largest, most diverse private jet fleet in the world, which grants anytime access to even the most remote destinations across the globe. To learn more about the leader in private aviation, visit netjets.com today.
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 49,000 commercial and 29,000 military aircraft engines. With a global team of approximately 53,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow and the future at www.geaerospace.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique ® to Enhance Customer Capabilities
YORK, Pa.--(BUSINESS WIRE)--BioTechnique ® LLC ('BioTechnique' or the 'Company') proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and freeze-drying of bacterial, viral, and mRNA-based vaccines, proteins, and other complex biologics. He holds a Ph.D. in Biotechnology Engineering from the Institute of Applied Biochemistry in Moscow, where his research focused on novel formulation and process control methods for lyophilization. After completing postdoctoral training with Professor Michael Pikal at the University of Connecticut, he went on to hold roles at Immunex, Wyeth, and Pfizer, contributing to industry-leading development efforts. Dr. Tchessalov is the founder of SN Lyophilization, a consulting firm dedicated to freeze-drying and parenteral drug product processing. With over 30 scientific publications to his name, his current work focuses on lyophilization scale-up and transfer, as well as processing operations including filtration, filling, freezing, and thawing. His partnership with BioTechnique strengthens the company's ability to support clients with practical, science-driven solutions across the entire drug product lifecycle. BioTechnique ® 's Lyophilization Capabilities At BioTechnique ®, lyophilization is a core competency backed by robust infrastructure and scientific expertise. Our state-of-the-art, aseptic manufacturing facility is equipped to support both clinical and commercial-scale freeze-drying of biologics, including monoclonal antibodies, peptides, vaccines, and other sensitive drug products. We offer flexible lyophilizer configurations, precise cycle development, and seamless tech transfer—all executed under strict cGMP conditions. Whether clients require formulation support, cycle optimization, troubleshooting, or full-process development, BioTechnique provides tailored solutions that prioritize product stability, yield, and regulatory compliance. With Dr. Tchessalov's guidance, our clients gain not only access to advanced modeling tools and industry best practices, but also the strategic insight needed to successfully navigate the complexities of lyophilization from early development through commercialization. For more information on BioTechnique's capabilities, visit
Business Wire
3 hours ago
- Business Wire
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the 'Company'), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. 'TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our TriNav ® product suite and proprietary PEDD ® platform across a broad range of solid tumor indications,' said Mary Szela, President and CEO of TriSalus. 'We are pleased to reaffirm our full-year revenue growth guidance of 50%, reflecting increasing market penetration within liver-directed therapies. We will continue to invest in clinical data to extend the benefits of our PEDD technology platform to new embolization applications. With a strategic shift toward partnering development of Nelitolimod and an expanded focus on liver-directed therapies and new applications, we are energized by the opportunity to bring our PEDD technology to a wider range of patients which will not only support improved clinical outcomes but also drive deeper physician engagement and commercial momentum, fueling our long-term vision.' Second Quarter 2025 Highlights Generated $11.2 million in net sales, a 52% increase year-over-year, and sequential growth of 22% over the first quarter 2025. Continued strong commercial momentum with expanded use of TriNav ® in liver embolization and continued to further develop new applications in new clinical settings focused on the interventional radiology specialty. Expanded product portfolio with the successful launch of TriNav ® FLX, the latest advancement in Pressure-Enabled Drug Delivery (PEDD). Designed with a more flexible distal tip, TriNav FLX enhances navigability through tortuous vessels—providing an effective solution for physicians previously limited by anatomical barriers to PEDD adoption. Early market response has been strong, with sales surpassing internal projections. Subsequent to the second quarter, the Company simplified its capital structure through the successful completion of an exchange offering of previously issued Series A Preferred stock. Second Quarter 2025 Financial Highlights Revenue, all from the sale of the TriNav system, was $11.2 million for the three months ended June 30, 2025, an increase of 52% compared to the same period in 2024 and 22% sequential growth. Revenue growth was driven primarily by increased selling resources and increased market share. Gross margins were 84% in the second quarter, compared to 88% in the same period of 2024. The year-over-year decline was primarily driven by lower manufacturing efficiency associated with newly launched products, a dynamic we expect to improve as production scales and processes mature over the course of the year. Research and Development (R&D) expenses were approximately $3.9 million, compared to $4.7 million for the same quarter of the prior year. The decline in R&D costs is primarily a result of a decline in clinical trial costs relating to Nelitolimod. Sales and Marketing (S&M) expenses were approximately $7.2 million in the second quarter, compared to $6.0 million for the same quarter of the prior year. The year-over-year increase reflects continued investment in the expansion of our commercial organization. General & Administrative (G&A) expenses were approximately $5.7 million, compared to $4.0 million for the same quarter of the prior year. G&A costs include non-cash stock-based compensation of $1.2 million and $0.7 million, respectively, for the same periods. The increase in G&A costs is primarily a result of professional services related to legal services and audit. Operating losses were $7.3 million, compared to Operating losses of $8.2 million for the same period in 2024. Current reductions in operating losses are due to reduced research and development expenses associated with the ramp-down of Nelitolimod clinical trial spending. Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million for the same period in 2024, primarily due to non-cash adjustments to the fair value of our contingent earnout liability. The basic and diluted loss per share was $0.27, compared to $0.21 for the same period in 2024. As of June 30, 2025, cash and cash equivalents totaled $26.5 million providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026. The non-GAAP measure of adjusted EBITDA is reconciled in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024. Currently, reductions in adjusted EBITDA losses are due to increased sales, reduced research and development expenses and increased stock compensation in 2025. Conference Call The Company will host a conference call and webcast today at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the investor relations section of TriSalus' website. A replay will also be available on the website following the event. About TriSalus Life Sciences TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading 'Risk Factors.' All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. TRISALUS LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands) December 31, 2024 Assets Current assets: Cash and cash equivalents $ 26,490 $ 8,525 Accounts receivable, net 5,571 5,087 Inventory, net 3,807 4,048 Prepaid expenses 2,216 3,009 Total current assets 38,084 20,669 Property and equipment, net 1,711 1,669 Right-of-use assets 1,103 1,210 Other assets 419 423 Total assets $ 41,317 $ 23,971 Liabilities and Stockholders' Deficit Current liabilities: Trade payables $ 1,902 $ 2,274 Accrued liabilities 7,078 7,355 Short-term lease liabilities 123 216 Other current liabilities 221 383 Total current liabilities 9,324 10,228 Long-term debt, net of unamortized discount and debt issuance costs 32,274 22,084 Revenue base redemption liability 358 507 Long-term lease liabilities 1,265 1,329 Contingent earnout liability 7,522 7,401 Warrant and SEPA liabilities 9,997 8,316 Total liabilities 60,740 49,865 Commitments and contingencies Stockholders' deficit: Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 3,594,002 and 3,985,002 shares at June 30, 2025, and December 31, 2024, respectively. — — Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 37,983,259 and 31,279,264 shares at June 30, 2025, and December 31, 2024, respectively. 3 3 Additional paid-in capital 278,786 253,652 Accumulated deficit (298,212 ) (279,549 ) Total stockholders' deficit (19,423 ) (25,894 ) Total liabilities and stockholders' deficit $ 41,317 $ 23,971 Expand Non-GAAP Financial Measure To supplement the financial results presented in accordance with GAAP, TriSalus has also included in this press release non-GAAP adjusted EBITDA, which excludes from net loss, income tax expense, interest expense, interest income, change in fair value of SEPA, warrant and revenue-base redemption liabilities, change in fair value of contingent earn out liability, stock-based compensation expense and depreciation. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. TriSalus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand TriSalus' business. TriSalus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, TriSalus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare TriSalus' results from period to period, and to identify operating trends in TriSalus' business.
Business Wire
3 hours ago
- Business Wire
First Trust Announces Elections/Re-Elections of Trustees for ETFs and Other Open-End Funds
WHEATON, Ill.--(BUSINESS WIRE)--At special meetings of shareholders held on August 12, 2025 (collectively, the 'Meetings'), shareholders of the open-end management investment companies (collectively, the 'OEFs/ETFs') consisting of the exchange-traded funds, mutual funds and variable insurance funds advised by First Trust Advisors L.P. ('FTA') approved proposals to elect or re-elect, as applicable, eight nominees to the Boards of Trustees (collectively, the 'Boards') of the OEFs/ETFs. The OEFs/ETFs include the following: First Trust Exchange-Traded Fund; First Trust Exchange-Traded Fund II; First Trust Exchange-Traded Fund III; First Trust Exchange-Traded Fund IV; First Trust Exchange-Traded Fund V; First Trust Exchange-Traded Fund VI; First Trust Exchange-Traded Fund VII; First Trust Exchange-Traded Fund VIII; First Trust Exchange-Traded AlphaDEX ® Fund; First Trust Exchange-Traded AlphaDEX ® Fund II; First Trust Series Fund; and First Trust Variable Insurance Trust. At each Meeting, each of the following individuals was elected or re-elected to the Board of the applicable OEF/ETF: James A. Bowen; Thomas J. Driscoll; Richard E. Erickson; Thomas R. Kadlec; Denise M. Keefe; Robert F. Keith; Niel B. Nielson; and Bronwyn Wright. Mr. Bowen is referred to as the 'Interested Trustee' of each OEF/ETF due to his position as Chief Executive Officer of FTA, and each of the other Trustees is referred to as an 'Independent Trustee.' FTA is a federally registered investment advisor and serves as the investment advisor to the series of the OEFs/ETFs. FTA and its affiliate, First Trust Portfolios L.P. ('FTP'), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services. FTA has collective assets under management or supervision of approximately $278 billion as of June 30, 2025 through unit investment trusts, exchange-traded funds, closed-end funds, mutual funds, variable insurance funds and separately managed accounts. FTA is the supervisor of the First Trust unit investment trusts, while FTP is the sponsor. FTP is also a distributor of mutual fund shares and exchange-traded fund creation units. FTA and FTP are based in Wheaton, Illinois.
